A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers
Carcinoma, Pancreatic Ductal
Tissue Array Analysis
MUC1 and MSLN were superior to pathologic features and other putative biomarkers as predicting survival group. Molecular assays comparing cancers from short and long survivors are an effective strategy to screen biomarkers and prioritize candidate cancer genes for diagnostic and therapeutic studies.